Fungal drug candidate, MYC-053, is effective against Candida auris
by Press Release from Outbreak News Today on (#3HNX2)
TGV Therapeutics, the pharmaceutical company developing first-in-class drugs for fighting antibiotic-resistant infections, announced it is working with the National Institutes of Health to expand its research on a drug that shows promise against new fungal superbugs. TGV Therapeutics and its advisors, Dr. George and Victor Tetz, said initial data indicate their drug candidate, MYC-053, is ["]
The post Fungal drug candidate, MYC-053, is effective against Candida auris appeared first on Outbreak News Today.